Booming antibodies 2001
MasterControl - Learn How to Avoid Obstacles in Pharma Manufacturing
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!

EdiGene and Immunochina Announce Research and Development Collaboration to Develop Allogeneic CAR-T Therapy for Cancer

Thursday, May 28, 2020

EdiGene, Inc., which develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, and Immunochina,a company dedicated to innovative gene and cellular technology, announced that they have formed a research and development collaboration to develop allogeneic CAR-T therapy for cancer.

Under this partnership, both companies will combine EdiGene’s expertise in genome editing and allogeneic T-cell process with Immunochina’s expertise in innovative CAR-T technology to develop potentially best-in-class allogeneic CAR-T therapeutics. Terms are not disclosed.

"EdiGene is a leading gene-editing company with cutting edge technology platform. It is our great pleasure to work with this team," said Ting He, Ph.D.,founder and CEO of Immunochina, "Make the Incurable Curable, which is Immunochina’s vision. We have accumulated considerable experience in late-stage hematological malignancies, with two IND approvals. Although a number of break throughs have been made by autologous T cells lately, allogeneic T cells could also play an important role in the future. The cooperation is a big step for both teams, and I believe we will make exciting discoveries together."

“We are excited to collaborate with Immunochina, one of the leading clinical-stage CAR-T companies,” said Dong Wei, Ph.D.,CEO of EdiGene, “We believe that allogeneic T-cell therapeutics has tremendous potential, by offering innovative T-cell therapies ‘off the shelf’ with more effective quality control and lower cost. By combining the expertise of EdiGene and Immunochina, we will be well positioned to develop such therapeutics and advance to clinics, one step closer to help the cancer patients in need.”

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEA Bora Pharmaceuticals - CMDO making success Medical Fair Asia 2022 Medical Manufacturing Asia 2022